Literature DB >> 19811509

3 Tesla magnetic resonance imaging with and without corticotropin releasing hormone stimulation for the detection of microadenomas in Cushing's syndrome.

Dana Erickson1, Bradley Erickson, Robert Watson, Alice Patton, John Atkinson, Fredric Meyer, Todd Nippoldt, Paul Carpenter, Neena Natt, Adrian Vella, Prabin Thapa.   

Abstract

OBJECTIVE: We sought to determine if higher resolution 3 Tesla (T) magnetic resonance imaging (MRI) with or without ovine corticotropin releasing hormone (o-CRH) stimulation would increase the sensitivity for detection of pituitary microadenomas in ACTH-dependent Cushing's syndrome (CS). DESIGN AND PATIENTS: We prospectively identified 23 patients over a 2-year period with clinical and biochemical evidence of ACTH-dependent CS with no lesion (n = 11) or equivocal lesion (n = 10) on 1.5T MRI. Subsequently, two additional MRIs were performed in random order: 3T nonstimulated MRI or 3T MRI with o-CRH in all patients. Three neuroradiologists reviewed all examinations in a randomized blinded fashion. Patients were divided into four groups, depending on the outcome of their evaluation and treatment for CS. Two patients had to be excluded, and so we report on 21 subjects. MEASUREMENTS AND
RESULTS: Both 3T MRI without (P < 0.016) and with o-CRH stimulation (P < 0.013) was significantly more sensitive for detection of pituitary microadenomas than 1.5T MRI for Group 1 (definitive proof of Cushing's disease, n = 10). Group 2 (those in group 1, plus three patients where dynamic/invasive testing suggested pituitary source) also showed a significant (P < 0.012) advantage for 3T. There was no difference between the 3T and the 3T o-CRH examinations for any of the pulse sequences. We did not observe a statistically significant difference in other patient groups [patients with recurrent CD (n = 6) and patients with ectopic CS (n = 2)].
CONCLUSIONS: The results of our prospective blinded studies suggest that 3T MRI of pituitary gland should be considered in evaluation of patients with ACTH-dependent CD when 1.5T imaging is negative or equivocal.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19811509     DOI: 10.1111/j.1365-2265.2009.03723.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

Review 1.  Pituitary magnetic resonance imaging in Cushing's disease.

Authors:  Giovanni Vitale; Fabio Tortora; Roberto Baldelli; Francesco Cocchiara; Rosa Maria Paragliola; Emilia Sbardella; Chiara Simeoli; Ferdinando Caranci; Rosario Pivonello; Annamaria Colao
Journal:  Endocrine       Date:  2016-07-19       Impact factor: 3.633

2.  Cavernous and inferior petrosal sinus sampling and dynamic magnetic resonance imaging in the preoperative evaluation of Cushing's disease.

Authors:  Matthew B Potts; Jugal K Shah; Annette M Molinaro; Lewis S Blevins; J Blake Tyrrell; Sandeep Kunwar; Christopher F Dowd; Steven W Hetts; Manish K Aghi
Journal:  J Neurooncol       Date:  2014-01-08       Impact factor: 4.130

3.  Intraoperative multiple-staged resection and tumor tissue identification using frozen sections provide the best result for the accurate localization and complete resection of tumors in Cushing's disease.

Authors:  Jung Soo Lim; Seung Ku Lee; Se Hoon Kim; Eun Jig Lee; Sun Ho Kim
Journal:  Endocrine       Date:  2011-06-19       Impact factor: 3.633

4.  Feasibility of high-resolution pituitary MRI at 7.0 tesla.

Authors:  Alexandra A J de Rotte; Anja G van der Kolk; Dik Rutgers; Pierre M J Zelissen; Fredy Visser; Peter R Luijten; Jeroen Hendrikse
Journal:  Eur Radiol       Date:  2014-05-29       Impact factor: 5.315

5.  A modified protocol using half-dose gadolinium in dynamic 3-Tesla magnetic resonance imaging for detection of ACTH-secreting pituitary tumors.

Authors:  Lesly Portocarrero-Ortiz; Dulce Bonifacio-Delgadillo; Arturo Sotomayor-González; Arturo Garcia-Marquez; Raul Lopez-Serna
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

Review 6.  Modern imaging in Cushing's disease.

Authors:  W A Bashari; D Gillett; J MacFarlane; A S Powlson; A G Kolias; R Mannion; D J Scoffings; I A Mendichovszky; J Jones; H K Cheow; O Koulouri; M Gurnell
Journal:  Pituitary       Date:  2022-06-06       Impact factor: 3.599

7.  MRI-negative Cushing's Disease: Management Strategy and Outcomes in 15 Cases Utilizing a Pure Endoscopic Endonasal Approach.

Authors:  Guive Sharifi; Amir Arsalan Amin; Mohammadmahdi Sabahi; Nikolas B Echeverry; Nader Akbari Dilmaghani; Seyed Ali Mousavinejad; Majid Valizadeh; Zahra Davoudi; Badih Adada; Hamid Borghei-Razavi
Journal:  BMC Endocr Disord       Date:  2022-06-09       Impact factor: 3.263

8.  Adrenocorticotropic hormone-producing pheochromocytoma: A case report.

Authors:  Vadim Krylov; Ekaterina Dobreva; Sergey Kharnas; Nikolay Kuzntesov; Vladimir Nikolenko; Evegenia Marova; Vladimir Motalov; Vladimir Levkin; Yury Zharikov; Mikhail Sinelnikov
Journal:  Int J Surg Case Rep       Date:  2020-02-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.